CoChat

Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review

Koshal, Prashant, Jamwal, Sumit, Kumar, Puneet · 2018 · Neuropharmacology
Cited by 44

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Epilepsy is one of the most prevalent neurological disorder affecting more than 50 million people worldwide. Numerous studies have suggested that an imbalance in glutamatergic (excitatory) and GABAergic (inhibitory) neurotransmitter system is one of the dominating pathophysiological mechanisms underlying the occurrence and progression of seizures. Further, this alteration in GABAergic and glutamatergic system disrupts the delicate balance of other neurotransmitters system in the brain. Emerging strides have documented the protective role of GLP‐1 signaling on altered neurotransmitters signaling in Epilepsy and associated co‐morbidities. GLP‐1 is neuropeptide and synthesized by preproglucagon (PPG) neurons in the brain. GLP‐1 receptors are widely distributed throughout the brain including hippocampus (CA3 and CA1 region) and implicated in various neurological disorders like Epilepsy. A complete understanding of alteration in neurotransmitters signaling will provide essential insight into the basic pathogenic mechanisms of epilepsy and may uncover novel targets for future drug therapies. Presently, treatment of epilepsy is palliative in nature, providing only symptomatic relief to patients. The apparent or traditional approach of treating epileptic subjects with anti‐epileptic drugs is associated with variety of adverse effects. Therefore, alternative approaches that can restore altered neurotransmitter signaling are being tried and adopted. Present review is an attempt to highlight the emerging protective role of GLP‐1 signaling on altered neurotransmitters signaling in epilepsy. Authors have made significant efforts to discuss effect of various GLP‐1 analogs on various neurotransmitters system and associated molecular and cellular pathways as a potential drug target for the management of epilepsy and associated co‐morbidities. This article is part of the Special Issue entitled ‘Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.’ HighlightsEpilepsy is one of the most prevalent neurological disorder.GLP‐1 analogs cross BBB and provide significant neuroprotection.GLP‐1R stimulation improves learning and memory.GLP‐1R stimulation balances altered neurotransmitters signaling in Epilepsy.GLP‐1 analogs are better therapeutic strategy to treat Epilepsy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2017.11.015

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 44

Metadata

Authors
Koshal, P., Jamwal, S., & Kumar, P.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2018-07
Volume
136
Issue
Pt B
Pages
271-279
ISSN
0028-3908 (ISSN-L)
OpenAlex
W2767594073
Cited by
44
References
12
FWCI
1.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review. https://app.cochat.ai/papers/10.1016/j.neuropharm.2017.11.015
The paper
Koshal, P., Jamwal, S., & Kumar, P. (2018). Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.11.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.